Surgical Treatment of Medullary Thyroid Cancer

2015 ◽  
pp. 187-205 ◽  
Author(s):  
Andreas Machens ◽  
Henning Dralle
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid

National Trends in the Surgical Treatment of Non-advanced Medullary Thyroid Cancer (MTC): An Evaluation of Adherence with the 2009 American Thyroid Association Guidelines

2016 ◽  
Vol 40 (12) ◽  
pp. 2930-2940 ◽  
Author(s):  
Eun Hae Estelle Chang ◽  
Waseem Lutfi ◽  
Joseph Feinglass ◽  
Alexandra Eudokia Reiher ◽  
Tricia Moo-Young ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Medullary Thyroid Cancer ◽  
American Thyroid Association ◽  
Medullary Thyroid ◽  
National Trends

scholarly journals Medullary Thyroid Cancer

1997 ◽  
Vol 4 (1) ◽  
pp. 25-29
Author(s):  
Michael G. Franz
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Medullary Thyroid Cancer ◽  
Early Stage ◽  
Medullary Carcinoma ◽  
Early Stage Disease ◽  
Medullary Thyroid ◽  
Central Lymph Node Dissection ◽  
Familial Tumors ◽  
Thyroid Malignancies

Background Medullary thyroid cancer, a tumor of the parafollicular C cells, accounts for approximately 10% of all thyroid malignancies. An estimated 75% of cases are sporadic, and the remaining 25% are familial. Methods The author reviews the clinical features and diagnostic tests for this entity, as well as the surgical treatment of recurrent or persistent medullary carcinoma. Results Sporadic medullary thyroid cancer typically presents as an isolated unilateral mass. Familial tumors tend to be multifocal and bilateral. In patients with multiple endocrine neoplasia type 2A, pheochromocytomas and parathyroid hyperplasia also may develop. Care is taken to avoid operating on a patient with occult pheochromocytoma. Total thyroidectomy and central lymph node dissection are the keys for successful surgical treatment. Conclusions Surgery is the cornerstone of treatment for medullary carcinoma of the thyroid. Genetic testing using the ret oncogene allows identification of individuals who are at risk for the disease or those with early-stage disease.

scholarly journals Calcitonin level in the postoperative period as a risk factor for persistence of medular thyroid cancer

2021 ◽  
pp. 9-18
Author(s):  
O. A. Tovkai ◽  
V. O. Palamarchuk ◽  
V. A. Smolyar ◽  
V. V. Kuts ◽  
R. M. Sichinava
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Postoperative Period ◽  
Predictive Value ◽  
Medullary Thyroid Cancer ◽  
Disease Stage ◽  
Clinical Recurrence ◽  
Medullary Thyroid ◽  
Group 1

Aim — to evaluate the possibility of using basal calcitonin levels in the postoperative period to assess the effectiveness of surgical treatment of medullary thyroid cancer and the likelihood of its persistence (recurrence). Materials and methods. A single-site retrospective study was conducted to assess results of surgical treatment of 194 patients (74.2 % women and 25.8 % men), from them148 (76.3 %) patients had primary forms of the disease (group 1) and 46 (23.8 %) the recurrent form (group 2). Primary surgery included thyroidectomy, supplemented with thecentral and lateral dissection of the neck. Patients in group 1 were divided into two subgroups depending on the postoperative calcitoninlevels: group 1A with normal calcitonin levels (≤ 18 pg/ml)and group 1B with hypercalcitoninemia (> 18 pg/ml). The quantitative­determination of blood serum calcitonin levels was performed using automatic immunochemiluminescent analyzer «MAGLUMI» («Snibe Diagnostic», China) in 1 week and 1 year after surgery. Accumulation and primary data processing were performed in MS Excel 2013, statistical processing was performed using StatPlus programs with descriptive statistics, parametric and nonparametric methods for testing statistical hypotheses (Student’s criteria, Mann-Whitney, Fisher angular transformation), analysis of conjugation tables, ROC-analysis. The results were considered statistically significantat p < 0.05. Results. The average duration of follow-up was 67.5 months. The results of surgery were analyzed in terms of absence or presence of clinical recurrence, calcitoninlevels in the early postoperative period (5 days) were used as a predictor. After 2 years of follow-up,normocalcitoninemiawas accompanied by recurrence in almost 2 % of cases, while hyper­calcitoninemia — in 61 % to 74 %, depending on the stage and frequency of the disease. The correlationsbetween postoperative calcitonin levels and presence of recurrence (persistence) of medullary thyroid cancer has been established: AUC = 0.928 (0.867; 0.989, Juden index (J) = 0.429, threshold (cut-off point) ≥ 28.1 pg/ml, sensitivity = 0.938 (0.854; 1,000), specificity = 0.855 (0.789; 0.920), predictive value of positive result(PPV) = 0.699, predictive value of negative resultPNV = 0.991. Moreover, countersensitivity scores and incidence of negative test results in patients with relapse depending on the level of postoperative calcitonin were calculated. Conclusions. Postoperative calcitonin levels in 5 days after surgery can be used for assessment of efficacy of the surgical treatment (AUC — 0,928 (0,867; 0,989), Juden index — 0,429)). The prognosis of recurrence-free disease does not depend on the disease stage. At calcitonin levels < 18 pg/ml, clinical signs of the disease persistence (recurrence) were detected in 1.5 % of cases (PNV = 0.991). The reliability of predicting the disease recurrence depended on the stage and frequency of surgery: PRV = 0.612 in primary forms without metasta­­ses, PRV = 0.825 in recurrent forms. Calcitonin values < 28.1 pg/ml can be considered a relatively «safe» level.

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

2014 ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Malgorzata Kowalska ◽  
Agnieszka Pawlaczek ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Receptor Expression ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation

Clinical usefulness of dynamic risk stratification in medullary thyroid cancer

2016 ◽  
Author(s):  
Ji Min Han ◽  
Hyemi Kwon ◽  
Won Gu Kim ◽  
Min Ji Jeon ◽  
Tae Yong Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Medullary Thyroid Cancer ◽  
Clinical Usefulness ◽  
Medullary Thyroid ◽  
Dynamic Risk

The impact of age and gender on the presentation and prognosis of medullary thyroid cancer - an Israeli multicenter study

2017 ◽  
Author(s):  
Orit Twito ◽  
Simona Grozinsky-Glasberg ◽  
Carlos Benbassat ◽  
Sigal Llevy ◽  
Gideon Bachar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Multicenter Study ◽  
Medullary Thyroid Cancer ◽  
Age And Gender ◽  
Medullary Thyroid ◽  
And Gender ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document